

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

DU4475

RRID:CVCL_1183

Type: Cell Line

Proper Citation

RRID:CVCL_1183

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1183

Proper Citation: RRID:CVCL_1183

Description: Cell line DU4475 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:221108](#), [PMID:10862037](#), [PMID:11343771](#), [PMID:11414198](#), [PMID:12068308](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:18397470](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Caution: Reported by some sites and publications to originate from a 62 year old woman, but the cell line was established when she was 70 year old., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BRAF genetic alteration cell panel (ATCC TCP-1032)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DU4475

Synonyms: Du4475, DU-4475, Du-4475, DU 4475, Du 4475, Duke University 4475

Cross References: CLO:CLO_0002842, EFO:EFO_0002168, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-7921, ATCC:HTB-123, BioGRID_ORCS_Cell_line:684, BioSample:SAMN03471772, BioSample:SAMN03473595, BioSample:SAMN05292453, BioSample:SAMN10987660, cancercellines:CVCL_1183, CCRID:1101HUM-PUMC000342, Cell_Model_Passport:SIDM01001, ChEMBL-Cells:ChEMBL3308261, ChEMBL-Targets:ChEMBL2366246, CLS:300371, Cosmic:685863, Cosmic:871141, Cosmic:904355, Cosmic:906844, Cosmic:921975, Cosmic:934523, Cosmic:997915, Cosmic:1046952, Cosmic:1047716, Cosmic:1091340, Cosmic:1152520, Cosmic:1287936, Cosmic:1289387, Cosmic:1609476, Cosmic:2164988, Cosmic-CLP:906844, DepMap:ACH-000258, DSMZ:ACC-427, DSMZCellDive:ACC-427, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:906844, GEO:GSM217568, GEO:GSM274659, GEO:GSM344345, GEO:GSM344395, GEO:GSM421865, GEO:GSM783961, GEO:GSM886989, GEO:GSM888058, GEO:GSM1053707, GEO:GSM1669746, IARC_TP53:21043, IGRhCellID:DU4475, LiGeA:CCL_395, LINCS_HMS:50577, LINCS_LDP:LCL-1323, PharmacDB:DU4475_310_2019, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1183, PubChem_Cell_line:CVCL_1183, SLKBase:3415, Wikidata:Q54831578

ID: CVCL_1183

Record Creation Time: 20220427T215824+0000

Record Last Update: 20260815T232722+0000

Ratings and Alerts

No rating or validation information has been found for DU4475.

Warning: Discontinued: ATCC; CRL-7921

Caution: Reported by some sites and publications to originate from a 62 year old woman, but the cell line was established when she was 70 year old., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BRAF genetic alteration cell panel (ATCC TCP-1032)., Group: Triple negative breast cancer (TNBC) cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. *Cancer research communications*, 6(2), 421.

Qasem H, et al. (2026) Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model. *Pharmaceutics*, 18(1).

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. *Cancer research communications*, 5(2), 375.

Zheng SM, et al. (2024) MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer. *Cancer research*, 84(9), 1460.

Lin CH, et al. (2023) Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. *Cancer gene therapy*, 30(3), 404.

Adams CM, et al. (2023) Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. *Cancer discovery*, 13(5), 1210.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. *Cell reports*, 42(12), 113503.

B??ckelmann LC, et al. (2021) YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. *Cellular oncology (Dordrecht)*, 44(5), 1183.

Gong Y, et al. (2021) Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. *Cell metabolism*, 33(1), 51.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Apostolidi M, et al. (2021) Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes. *Cancer research*, 81(16), 4346.

Johnstone CN, et al. (2020) FGF13 promotes metastasis of triple-negative breast cancer. *International journal of cancer*, 147(1), 230.

Au CC, et al. (2020) Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. *eLife*, 9.

Yomtoubian S, et al. (2020) Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. *Cell reports*, 30(3), 755.

Kim JJ, et al. (2020) PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells. *Molecular cell*, 80(2), 327.

Lukey MJ, et al. (2019) Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. *Cell reports*, 29(1), 76.